Bioactivation of drugs: Risk and drug design

Annual Review of Pharmacology and Toxicology

Volumn 51, Issue , 2011, Pages 145-167

  Walsh, John S ^a   Miwa, Gerald T ^b  

^a DMPK Consulting   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

electrophiles; fluorination; oxidative stress; radicals; structural alerts

Indexed keywords

ALPIDEM; ATENOLOL; BICALUTAMIDE; BISOPROLOL; CIPROFLOXACIN; FELBAMATE; FLINDOKALNER; FLUTAMIDE; HETEROCYCLIC COMPOUND; METOPROLOL; NEFAZODONE; NEVIRAPINE; NILUTAMIDE; OLANZAPINE; PIPERANOMETOZINE; PRACTOLOL; PRIMAQUINE; PRINOMIDE; QUINONE DERIVATIVE; SITAGLIPTIN; SUDOXICAM; TACRINE; TIENILIC ACID; TINIDAZOLE; TRIMETHOPRIM; TROVAFLOXACIN; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON; ZOLPIDEM;

AEROBIC METABOLISM; AGRANULOCYTOSIS; APLASTIC ANEMIA; ARTICLE; AUTOIMMUNE HEPATITIS; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG ACTIVATION; DRUG DESIGN; DRUG METABOLISM; DRUG OXIDATION; DRUG SAFETY; DRUG STRUCTURE; FLUORINATION; GASTROINTESTINAL TOXICITY; HEPATITIS; HUMAN; LIVER TOXICITY; METHEMOGLOBINEMIA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SCLEROSING PERITONITIS; X RAY CRYSTALLOGRAPHY;

BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; HUMANS; OXIDATIVE STRESS; PEROXIDASES; PHARMACEUTICAL PREPARATIONS;

EID: 79951990726     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010510-100514     Document Type: Article

References (85)

1. Conti A, Bickel MH. 1977. History of drug metabolism: discoveries of the major pathways in the 19th century. Drug Metab. Rev. 6:1-50 (Pubitemid 8124183)
2. Gibson GG, Skett P. 2001. Introduction to Drug Metabolism. Cheltenham, United Kingdom: Nelson Thornes. 244 pp. 3rd ed.
3. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. 2005. The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45:177-202 (Pubitemid 40261802)
4. Erion MD, van Poelje PD, MacKenna DA, Colby TJ, Montag AC, et al. 2005. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312:554-60 (Pubitemid 40189552)
5. Duan J-X, Jiao H, Kaizerman J, Stanton T, Evans JW, et al. 2008. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J. Med. Chem. 51:2412-20 (Pubitemid 351628502)
6. Guengerich FP. 2001. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 14(6):611-50 (Pubitemid 32565712)
7. Tukey RH, Strassburg CP. 2000. Human UDP-glucuronosyltransferases: metabolism, expression and disease. Annu. Rev. Pharmacol. Toxicol. 40:581-616 (Pubitemid 30340694)
8. O'Brien PJ. 2000. Peroxidases. Chem. Biol. Interact. 129:113-39 (Pubitemid 32061057)
9. Tafazoli S, O'Brien PJ. 2005. Peroxidases: a role in the metabolism and side effects of drugs. Drug Discov. Today 10(9):617-25 (Pubitemid 40704769)
10. Sallustio BC, Sabordo L, Evans AM, Nation RL. 2000. Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1:163-80
11. Ortiz de Montellano PR, ed. 2005. Cytochrome P450: Structure, Mechanism, and Biochemistry. New York: Kluwer Academic/Plenum 3rd ed.
12. Guengerich FP. 2001. Uncommon P450-catalyzed reactions. Curr. Drug Metab. 2:93-115 (Pubitemid 32536997)
13. Auclair K, Zhengbo H, Little DM, Ortiz de Montellano PR, Groves JT. 2002. Revisiting the mechanism of P450 enzymes with the radical clocks norcarane and spiro[2,5]octane. J. Am. Chem. Soc. 124:6020-27 (Pubitemid 34552846)
14. NewcombM,Chandrasena REP, Lansakara-P DSP, Kim HY, Lippard SJ,etal. 2007. Desaturase reactions complicate the use of norcarane as a mechanistic probe. Unraveling the mixture of twenty-plus products formed in enzyme-catalyzed oxidations of norcarane. J. Org. Chem. 72:1121-27
15. Evans DC, Watt AP, Nicoll-Griffith DA, Baillie TA. 2004. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17:3-16 (Pubitemid 38134055)
16. Davies MJ, Hawkins CL, Pattison DI, Rees MD. 2008. Mammalian heme peroxidases: from molecular mechanisms to health implications. Antioxid. Redox Signal. 10(7):1199-234 (Pubitemid 351634397)
17. Lai WG, Gardner I, Zahid N, Uetrecht JP. 2000. Bioactivation and covalent binding of hydroxyfluper-lapine in human neutrophils: implications for fluperlapine-induced agranulocytosis. Drug Metab. Dispos. 28:255-63 (Pubitemid 30137048)
18. Tafazoli S, Spehar DD, O'Brien PJ. 2005. Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab. Rev. 37:311-25 (Pubitemid 40677507)
19. Remmel RP. 2002. Review of human UDP-glucuronyl transferases and their role in drug-drug interactions. Drugs Pharm. Sci. 116:89-121
20. Spahn-Langguth H, Benet LZ. 1992. Acyl glucuronides revisited: is the glucuronidation process a toxifi-cation as well as a detoxification mechanism? Drug Metab. Rev. 24(1):5-47
21. Bailey MJ, Dickinson RG 2003. Acyl glucuronide reactivity in perspective: biological consequences. Chem. Biol. Interact. 145(2):117-37 (Pubitemid 36398426)
22. Kalgutkar AS, Gardner I, Obach RS, Shaffer CL, Callegari E, et al. 2005. A comprehensive listing of bioactivation pathways of organic functional groups. Curr. Drug Metab. 6:161-225 (Pubitemid 40753853)
23. Uetrecht JP, Zahid N, Whitfield D. 1994. Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J. Pharmacol. Exp. Ther. 270(3):865-72 (Pubitemid 24315198)
24. Vasquez-Vivar J, Augusto O. 1993. Oxidative activity of primaquine metabolites on rat erythrocytes in vitro and in vivo. Biochem. Pharmacol. 47(2):309-16
25. Lai WG, Zahid N, Uetrecht JP. 1999. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J. Pharmacol. Exp. Ther. 291(1):292-99 (Pubitemid 29451602)
26. Kalgutkar AS, VazADN, Lame ME, Henne KR, SogliaJ, etal. 2005. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 33:243-53 (Pubitemid 40216592)
27. Madden S, Spaldin V, Hayes RN, Woolf TF, Pool WF, Park BK. 1995. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 25(1):103-16
28. Dalvie DK, Kalgutkar AS, Khojasteh-Bakht SC, Obach RS, O'Donnell JP. 2002. Biotransformation reactions of five-membered aromatic heterocyclic rings. Chem. Res. Toxicol. 15(3):269-99 (Pubitemid 34241365)
29. Egger H, Itterly W, John V, Rodebaugh R, Shimanskas C, et al. 1988. Disposition and metabolism of prinomide in laboratory animals. Drug Metab. Dispos. 16(4):568-75
30. Scott PW, Wood SG, Chasseaud LF, Matthews RW, Henrick K 1985. A novel metabolite of tinidazole involving nitro-group migration. Biochem. Pharmacol. 34(3):457-58 (Pubitemid 15163172)
31. Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, et al. 2005. Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic a, p-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem. Res. Toxicol. 18(9):1427-37 (Pubitemid 41361716)
32. Mansuy D, Dansette PM. 1996. New biological reactive intermediates. metabolic activation of thiophene derivatives. Adv. Exp. Med. Biol. 387:1-6 (Pubitemid 26259222)
33. Lopez Garcia MP, Dansette PM, Valadon P, Amar C, Beaune PH, et al. 1993. Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. Eur. J. Biochem. 213(1):223-32 (Pubitemid 23106050)
34. Joshi EM, Heasley BH, Chordia MD, Macdonald TL. 2004. In vitro metabolism of 2-acetlybenzothiophene: relevance to zileuton hepatotoxicity. Chem. Res. Toxicol. 17:137-43 (Pubitemid 38252492)
35. Obach RS, Kalgutkar AS, Ryder TF, Walker GS. 2008. In vitro metabolism and covalent binding of enol-carboxamide derivatives and anti-inflammatory agents sudoxicam and meloxicam: insights into hepatotoxicity of sudoxicam. Chem. Res. Toxicol. 21(9):1890-99
36. Waldhauser L, Uetrecht J. 1991. Oxidation of propylthiouracil to reactive metabolites by activated neutrophils. Implications for agranulocytosis. Drug Metab. Dispos. 19:354-59
37. Ziegler-Skylakakis K, Nill S, Pan JF, Andrae U. 1998. S-oxygenation of thiourea results in the formation of genotoxic products. Environ. Mol. Mutagen. 31:362-73 (Pubitemid 28308467)
38. Otoikhian A, Simoyi RH, Petersen JL. 2005. Oxidation of dimethylthiourea metabolite by iodine and acidified iodate: N,N-dimethylaminoiminomethanesulfinic acid. Chem. Res. Toxicol. 18(7):1167-77 (Pubitemid 41022850)
39. Alvarez-Sanchez R, MontavonF, Hartung T, Pahler A. 2006. Thiazolidinedione bioactivation: a comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry. Chem. Res. Toxicol. 19:1106-16 (Pubitemid 44384842)
40. Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, et al. 1997. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab. Dispos. 25(5):573-83 (Pubitemid 27213098)
41. SchmidJ, Busch U, Trummlitz G, Prox A, Kaschke S, Wachsmuth H. 1995. Meloxicam: metabolic profile and biotransformation products in the rat. Xenobiotica 25(11):1219-36
42. Huskey SW, Doss GA, Miller RR, Schoen WR, Chiu SH. 1994. N-glucuronidationreactions. II. Relative N-glucuronidation reactivity of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole in rat, monkey, and human hepatic microsomes. Drug Metab. Dispos. 22(4):651-58 (Pubitemid 24244878)
43. Mutlib A, Chen H, Shockcor J, Espina R, Chen S, et al. 2000. Characterization of novel glutathione adducts of a non-nucleoside reverse transcriptase inhibitor, (S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl) -3,4-dihydro-2(1H)-quinazolinone (DP961), in rats. Possible formation of an oxirene metabolic intermediate from a disubstituted alkyne. Chem. Res. Toxicol. 13:775-84 (Pubitemid 30663456)
44. Tang-Liu DD, Matsumoto RM, Usansky JI. 1999. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin. Pharmacokinet. 37(4):273-87 (Pubitemid 29515694)
45. Kondo S, Kuchiki A, Yamamoto K, Akimoto K, Takahashi K, et al. 1980. Identification of nifedipine metabolites and their determination by gas chromatography. Chem. Pharm. Bull. 28:1-7 (Pubitemid 10092280)
46. Durand A, Thenot JP, Bianchetti G, Morselli PL. 1992. Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem. Drug Metab. Rev. 24(2):239-66
47. Shaffer CL, Harriman S, Koen YM, Hanzlik RP. 2001. Formation of cyclopropanone during cytochrome P450-catalyzed N-dealkylation of a cyclopropylamine.J. Am. Chem. Soc. 124:8268-74 (Pubitemid 34875386)
48. Sun Q, Zhu R, Foss FWJr, Macdonald TL. 2007. Mechanism of trovafloxacin hepatotoxicity: studies of a model cyclopropylamine-containing system. Bioorg. Med. Chem. Lett. 17:6682-86 (Pubitemid 350061330)
49. Dieckhaus CM, Miller TA, Sofia RD, Macdonald TL. 2000. A mechanistic approach to understanding species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Drug Metab. Dispos. 28(7):814-22 (Pubitemid 30470832)
50. Roecklein BA, Sacks HJ, Mortko H, Stables J. 2007. Fluorofelbamate. Neurotherapeutics 4:97-101 (Pubitemid 46107331)
51. Kalgutkar AS, Driscoll J, Zhao SX, Walker GS, Shepard RM, et al. 2007. A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif. Chem. Res. Toxicol. 20:1954-65
52. Wu Y-J, Davis CD, Dworetzky S, Fitzpatrick WC, Harden D, et al. 2003. Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4- fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition. J. Med. Chem. 46(18):3778-81 (Pubitemid 37034130)
53. Beconi MG, Reed JR, Teffera Y, Xia Y-Q, Kochansky CJ, et al. 2007. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab. Dispos. 35(4):525-32 (Pubitemid 46513254)
54. Zhang D, Ogan M, Gedamke R, Roongta V, Dai R, et al. 2003. Protein covalent binding of maxipost through a cytochrome P450-mediated ortho-quinone methide intermediate in rats. Drug Metab. Dispos. 31(7):837-45 (Pubitemid 36759052)
55. Thompson DC, Perera K, London R. 2000. Spontaneous hydrolysis of 4-trifluoromethylphenol to a quinone methide and subsequent protein alkylation. Chem. Biol. Interact. 126:1-14 (Pubitemid 30417476)
56. Rogers WI, Hartman AC, Palm PE, Okstein C, Kensler CJ. 1969. The fate of 5-trifluoromethyl-2'-deoxyuridine in monkeys, dogs, mice, and tumor-bearing mice. Cancer Res. 29:953-61
57. Bornstein J, Leone SA, Sullivan WF, Bennett OF. 1957. Facile hydrolysis of the trifluoromethyl group in the presence of base. Some trifluoromethylated indoles. J. Am. Chem. Soc. 79:1745-48
58. Aust SD, Chignell CF, Bray TM, Kalyanaraman B, Mason RP. 1993. Free radicals in toxicology. Toxicol. Appl. Pharmacol. 120:168-78 (Pubitemid 23203320)
59. Varga M. 1992. Understanding the role of oxyradicals in general and in toxic hepatic damage can help safer drug design. Med. Hypotheses 39(2):133-36
60. Azzi A, Davies KJA, Kelly F. 2004. Free radical biology-terminology and critical thinking. FEBS Lett. 558:3-6 (Pubitemid 38167400)
61. Ortiz de Montellano PR. 1990. Free radical modification of prosthetic heme groups. Pharmacol. Ther. 48:95-120 (Pubitemid 20322220)
62. Moonen HJ, Briede JJ, van Maanen JM, Kleinjans JC, de Kok TM. 2002. Generation of free radicals and induction of DNA adducts by activation of heterocyclic aromatic amines via different metabolic pathways in vitro. Mol. Carcinog. 35(4):196-203 (Pubitemid 36056714)
63. Albano E, Parola M, Comoglio A, Dianzani MU. 1993. Evidence for the covalent binding of hydroxyethyl radicals to rat liver microsomal proteins. Alcohol Alcohol. 28(4):453-59 (Pubitemid 23242779)
64. Scatena R, Bottoni P, Botta G, Martorana GE, Giardina B. 2007. The role of mitochondria in pharma-cotoxicology: a reevaluation of an old, newly emerging topic. Am. J. Physiol. Cell Physiol. 293(1):12-21
65. Slater AFG, Stefan C, Nobel I, Van Den Dobbelsteen DJ, Orrenius S. 1995. Signalling mechanisms and oxidative stress in apoptosis. Toxicol. Lett. 82/83:149-53 (Pubitemid 26054701)
66. Kappus H. 1986. Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem. Pharmacol. 35(1):1-6 (Pubitemid 16161353)
67. Cairo G, Recalcati S, Pietrangelo A, Minotti G. 2002. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic. Biol. Med. 32(12):1237-43 (Pubitemid 34607627)
68. Sorg O. 2004. Oxidative stress: a theoretical model or a biological reality? C. R. Biol. 327:649-62 (Pubitemid 38992409)
69. Squella JA, Bollo S, Nunez-Vergara LJ. 2005. Recent developments in the electrochemistry of some nitro compounds of biological significance. Curr. Org. Chem. 9(6):565-81 (Pubitemid 40584902)
70. Bolton JL, Trush MA, Penning TM, Dryhurst G, Monks TJ. 2000. Role of quinones in toxicology. Chem. Res. Toxicol. 13(3):135-60 (Pubitemid 30169958)
71. Kovacic P, Cooksy A. 2005. Iminium metabolite mechanism for nicotine toxicity and addiction: oxidative stress and electron transfer. Med. Hypotheses 64:104-11 (Pubitemid 39469246)
72. Kovacic P. 2007. Unifying mechanism for anticancer agents involving electron transfer and oxidative stress: clinical implications. Med. Hypotheses 69:510-16 (Pubitemid 47043281)
73. Kovacic P, Cooksy AL. 2005. Unifying mechanism for toxicity and addiction by abused drugs: electron transfer and reactive oxygen species. Med. Hypotheses 64:357-66 (Pubitemid 40022677)
74. Fau D, Berson A, Eugene D, Fromenty B, Fisch C, Pessayre D. 1992. Mechanism for the hepatotoxicity of the antiandrogen, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. J. Pharmacol. Exp. Ther. 263(1):69-77
75. Eghbal MA, Tafazoli S, Pennefather P, O'Brien PJ. 2004. Peroxidase catalysed formation of cytotoxic prooxidant phenothiazine free radicals at physiological pH. Chem. Biol. Interact. 151:43-51 (Pubitemid 39647936)
76. Pattison DI, Davies MJ. 2006. Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr. Med. Chem. 13:3271-90 (Pubitemid 44669775)
77. Jeng W, Ramkissoon A, Parman T, Wells PG. 2006. Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal degeneration. FASEB J. 20:638-50 (Pubitemid 44933308)
78. Shvedova AA, Kommineni C, Jeffries BA, Castranova V, Tyurina YY, et al. 2000. Redox cycling of phenol induces oxidative stress in human epidermal keratinocytes. J. Investig. Dermatol. 114(2):354-64 (Pubitemid 30417773)
79. Verma RP, Kapur S, Barberena O, Shusterman A, Hansch CH, Selassie CD. 2003. Synthesis, cytotoxicity, and QSAR analysis of X-thiophenols in rapidly dividing cells. Chem. Res. Toxicol. 16:276-84 (Pubitemid 36373692)
80. Galati G, Tafazoli S, Sabzevari O, Chan TS, O'Brien PJ. 2002. Idiosyncratic NSAID drug induced oxidative stress. Chem. Biol. Interact. 142(1-2):25-41 (Pubitemid 35232551)
81. Galati G, Sabzevari O,Wilson JX, O'Brien PJ. 2002. Prooxidant activity and cellular effectsof the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology 117:91-104 (Pubitemid 34786247)
82. Zhang L, Gao H, Hansch C, Selassie CD. 1998. Molecular orbital parameters and comparative QSAR in the analysis of phenol toxicity to leukemia cells. J. Chem. Soc. Perkin Trans. 2 2:2553-56 (Pubitemid 128435021)
83. Moridani MY, Siraki A, O'Brien PJ. 2003. Quantitative structure toxicity relationships for phenols in isolated rat hepatocytes. Chem. Biol. Interact. 145:213-23 (Pubitemid 36398434)
84. Doss GA, Baillie TA. 2006. Addressing metabolic activation as an integral component of drug design. Drug. Metab. Rev. 38:641-49 (Pubitemid 44903260)
85. Shin NY, Liu Q, Stamer SL, Liebler DC. 2007. Protein targets of reactive electrophiles in human liver microsomes. Chem. Res. Toxicol. 20:859-67 (Pubitemid 47035339)